Pharmacologic inhibition of JAK-STAT signaling promotes hair growth

Harel, Sivan; Higgins, Claire A.; Cerise, Jane E.; Dai, Zhijun; Chen, James C.; Clynes, Raphael; Christiano, Angela M.

doi:10.1126/sciadv.1500973

Cited by 192 publications

(192 citation statements)

References 75 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…A recent study of normal murine cycling hair demonstrated that JAK signaling induces a telogen block, preventing the hair from entering anagen phase and that JAK inhibitors induce anagen hair growth similar to a hedgehog pathway agonist (15). Another study demonstrated upregulation of pSTAT1 and pSTAT3 signaling in hair follicles in AA but not normal hair follicles due to IFN-γ signaling (5), supporting the idea that immune dysregulation enforces a similar hair cycle arrest.…”

Section: Discussionmentioning

confidence: 65%

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

Crispin¹,

Ko²,

Craiglow³

et al. 2016

JCI Insight

Self Cite

265

222

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 65%

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

Crispin¹,

Ko²,

Craiglow³

et al. 2016

JCI Insight

Self Cite

265

222

View full text Add to dashboard Cite

“…A study of normal murine cycling hair proved that JAK signaling induces a telogen block, preventing the hair from entering the anagen phase, and that JAK inhibitors induce anagen hair growth similar to a hedgehog pathway agonist [26]. …”

Section: Discussionmentioning

confidence: 99%

Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

2018

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is a common autoimmune disorder characterized by patchy hair loss. There are many treatments available for AA. However, treatments of severe forms of AA are not satisfactory. Recently, oral Janus kinase (JAK) inhibitors were found to be effective for the treatment of severe AA variants. Objective: The aim of this work was to evaluate and compare the efficacy, side effects, and durability of two oral JAK inhibitor medications (ruxolitinib and tofacitinib) in the treatment of severe AA. Methods: This study included 75 patients with AA with more than 30% scalp hair loss, alopecia totalis, and alopecia universalis randomized into 2 groups. The first group (n = 38) received ruxolitinib 20 mg twice daily, and the second group (n = 37) received oral tofacitinib 5 mg twice daily. The treatment continued for 6 months followed by 3 months of follow-up off therapy. Efficacy of treatment was assessed by monitoring the change in the Severity of Alopecia Tool (SALT) score. Results: Both tofacitinib and ruxolitinib induced remarkable hair regrowth, with a mean change in SALT score of 93.8 ± 3.25 in the ruxolitinib group and 95.2 ± 2.69 in the tofacitinib group. However, the ruxolitinib group showed a shorter duration for initial hair regrowth. There was no statistically significant difference between the groups regarding hair regrowth at the end of the 6-month treatment and relapse rate at the end of the 3-month follow-up. Around two thirds of cases experienced relapse. Both drugs were well tolerated, with no reported serious adverse effects. Conclusion: Both ruxolitinib and tofacitinib could be considered effective and well-tolerated treatments for extensive AA.

show abstract

“…During the course of the study, the authors noticed unexpected regrowth of HFs after topical treatment with JAK-STAT inhibitors. They checked it in a separate study and were able to demonstrate direct stimulation of HFs growth both in mice, and the human xenografts and HF organ culture model [64]. Moreover, treatment of human DP spheres with the inhibitor of JAK1/3 signaling tofacitinib enhanced inductivity of human DP cells grown in spheres signiicantly which resulted in larger and signiicantly greater numbers of HFs obtained in the patch assay.…”

Section: Dermal Papilla Cells and Their Inductive Propertiesmentioning

confidence: 99%

“…Nevertheless, many studies with DP cells have been conducted recently using 3D cultivation [3131, 64,67,68]. They showed prolongation of speciic markers expression and enhancement of hair inductive capacity after preliminary DP cell aggregation [42,43,66].…”

Section: Dermal Papilla Cells and Their Inductive Propertiesmentioning

confidence: 99%

Hair Follicle Reconstruction and Stem Cells

Kalabusheva¹,

Chermnykh²,

Terskikh³

et al. 2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

De novo hair follicle (HF) formation in embryonic skin and hair growth in postnatal skin are the result of epithelial-mesenchymal interactions between specialized mesenchymal dermal papilla (DP) and epithelial stem cells that give rise to hairs. Adult HF is a valuable source of diferent lineages of stem cells (SCs) with morphogenetic potential. Epithelial stem cells are residing in the special compartment of HF (the bulge) and can be mobilized to regenerate the new follicle with each hair cycle and to reepithelialize epidermis during wound repair. This review summarizes the current knowledge on key characteristics of HF SC populations in terms of regenerative potential. General biological principles that govern the mesenchymal-epithelial interactions within the HF and the signaling pathways that control HF development are discussed. The main focus is on recent approaches to reconstruct folliculogenesis in vitro and perspectives of the tissue engineering in alopecia therapy.

show abstract

Pharmacologic inhibition of JAK-STAT signaling promotes hair growth

Abstract: Topical treatment of mouse and human skin with small-molecule inhibitors of the JAK-STAT pathway results in hair growth.

Cited by 192 publications

References 75 publications

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

Hair Follicle Reconstruction and Stem Cells

Contact Info

Product

Resources

About